I overensstemmelse med virkningsmekanisme reducerer rosiglitazon i kombination med metformin insulinresistens og forbedret pankreatisk β- celle.
Consistent with the mechanism of action, rosiglitazone in combination with metformin reduced insulin resistance and improved pancreatic ß-cell function.